ScreenPoint Medical receives greenlight for Transpara™ 1.6.0. to reduce read times.
ScreenPoint Medical received clearance Monday from the U.S. Food & Drug Administration (FDA) for the first artificial-intelligence solution functional for both 2D and 3D mammography.
The greenlight for the solution, Transpara™ 1.6.0, expands ScreenPoint’s existing global marekt for Transpara 3D technology.
“This is a major breakthrough from ScreenPoint Medical, and it means that our new and existing U.S. customers now have access to the power of Transpara 3D for the first time,” ScreenPoint Chief Executive Officer Nico Karssemeijer said in a statement. “Multiple independent peer-reviewed publications have already demonstrated that Transpara significantly improves accuracy in 2D mammography, now the same applies for 3D.”
The company earned FDA clearance by demonstrating, through a clinical reader study, that radiologist accuracy improved when they read 3D mammograms while using Transpara. Additionally, according to study results, their reading time fell to approximately 35 seconds, roughly the same as the time needed for reading 2D mammograms.
Alongside reduced turn-around time, ScreenPoint officials also said the Transpara™ 1.6.0. interface was re-designed, using the company’s patented co-registration slice technology, to, potentially, maximize reading workflow.
Based on company information, Transpara has clinical installations in 15 countries, and it will be marketed in the United States by ScreenPoint Medical Inc., Siemens Healthineers USA, and Volpara Solutions.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 31st 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 31st 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.